| Tumor mutational load predicts survival after immunotherapy across multiple cancer types RM Samstein, CH Lee, AN Shoushtari, MD Hellmann, R Shen, ... Nature genetics 51 (2), 202-206, 2019 | 3179 | 2019 |
| Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients A Zehir, R Benayed, RH Shah, A Syed, S Middha, HR Kim, P Srinivasan, ... Nature medicine 23 (6), 703-713, 2017 | 2980 | 2017 |
| OncoKB: a precision oncology knowledge base D Chakravarty, J Gao, S Phillips, R Kundra, H Zhang, J Wang, ... JCO precision oncology 1, 1-16, 2017 | 2035 | 2017 |
| First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement J Tabernero, GI Shapiro, PM LoRusso, A Cervantes, GK Schwartz, ... Cancer discovery 3 (4), 406-417, 2013 | 774 | 2013 |
| Phase II Trial of the CDK4 Inhibitor PD0332991 in Patients With Advanced CDK4-Amplified Well-Differentiated or Dedifferentiated Liposarcoma MA Dickson, WD Tap, ML Keohan, SP D'Angelo, MM Gounder, ... Journal of clinical oncology 31 (16), 2024-2028, 2013 | 470 | 2013 |
| Sorafenib for advanced and refractory desmoid tumors MM Gounder, MR Mahoney, BA Van Tine, V Ravi, S Attia, HA Deshpande, ... New England Journal of Medicine 379 (25), 2417-2428, 2018 | 382 | 2018 |
| The management of desmoid tumours: a joint global consensus-based guideline approach for adult and paediatric patients B Alman, S Attia, C Baumgarten, C Benson, JY Blay, S Bonvalot, ... European Journal of Cancer 127, 96-107, 2020 | 338 | 2020 |
| What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC) A Drilon, G Li, S Dogan, M Gounder, R Shen, M Arcila, L Wang, ... Annals of Oncology 27 (5), 920-926, 2016 | 308 | 2016 |
| Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment SP D’Angelo, AN Shoushtari, NP Agaram, D Kuk, LX Qin, RD Carvajal, ... Human pathology 46 (3), 357-365, 2015 | 305 | 2015 |
| Progression-free survival among patients with well-differentiated or dedifferentiated liposarcoma treated with CDK4 inhibitor palbociclib: a phase 2 clinical trial MA Dickson, GK Schwartz, ML Keohan, SP D’Angelo, MM Gounder, P Chi, ... JAMA oncology 2 (7), 937-940, 2016 | 289 | 2016 |
| Inactivation of DNA-dependent protein kinase by protein kinase Cδ: implications for apoptosis A Bharti, SK Kraeft, M Gounder, P Pandey, S Jin, ZM Yuan, SP Lees-Miller, ... Molecular and cellular biology, 1998 | 275 | 1998 |
| Activity of Sorafenib against desmoid tumor/deep fibromatosis MM Gounder, RA Lefkowitz, ML Keohan, DR D'Adamo, M Hameed, ... Clinical Cancer Research 17 (12), 4082-4090, 2011 | 267 | 2011 |
| Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study M Gounder, P Schöffski, RL Jones, M Agulnik, GM Cote, VM Villalobos, ... The Lancet Oncology 21 (11), 1423-1432, 2020 | 265 | 2020 |
| SMARCA4-deficient thoracic sarcomatoid tumors represent primarily smoking-related undifferentiated carcinomas rather than primary thoracic sarcomas N Rekhtman, J Montecalvo, JC Chang, D Alex, RN Ptashkin, N Ai, ... Journal of Thoracic Oncology 15 (2), 231-247, 2020 | 221 | 2020 |
| Pharmacovigilance and reporting oversight in US FDA fast-track process: bisphosphonates and osteonecrosis of the jaw BJ Edwards, M Gounder, JM McKoy, I Boyd, M Farrugia, C Migliorati, ... The lancet oncology 9 (12), 1166-1172, 2008 | 190 | 2008 |
| Phase IB study of selinexor, a first-in-class inhibitor of nuclear export, in patients with advanced refractory bone or soft tissue sarcoma MM Gounder, A Zer, WD Tap, S Salah, MA Dickson, AA Gupta, ... Journal of Clinical Oncology 34 (26), 3166-3174, 2016 | 160 | 2016 |
| Objective response rate among patients with locally advanced or metastatic sarcoma treated with talimogene laherparepvec in combination with pembrolizumab: a phase 2 clinical trial CM Kelly, CR Antonescu, T Bowler, R Munhoz, P Chi, MA Dickson, ... JAMA oncology 6 (3), 402-408, 2020 | 143 | 2020 |
| Combined KIT and CTLA-4 blockade in patients with refractory GIST and other advanced sarcomas: a phase Ib study of dasatinib plus ipilimumab SP D'Angelo, AN Shoushtari, ML Keohan, MA Dickson, MM Gounder, ... Clinical Cancer Research 23 (12), 2972-2980, 2017 | 134 | 2017 |
| Clinical and morphologic characteristics of MEK inhibitor–associated retinopathy: differences from central serous chorioretinopathy JH Francis, LA Habib, DH Abramson, LA Yannuzzi, M Heinemann, ... Ophthalmology 124 (12), 1788-1798, 2017 | 114 | 2017 |
| Ultra‐rare sarcomas: a consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities S Stacchiotti, AM Frezza, JY Blay, EH Baldini, S Bonvalot, JVMG Bovée, ... Cancer 127 (16), 2934-2942, 2021 | 112 | 2021 |
